Target intelligence / Profile preview

Nicotinic acetylcholine receptor α9α10 subtype (α9α10 nAChR)

Target
α9α10 nAChR
Molecular classification
Ion channel, Receptor
01

Overview

The nicotinic acetylcholine receptor α9α10 subtype (α9α10 nAChR) is a heteropentameric ligand-gated ion channel primarily composed of α9 and α10 subunits, forming stoichiometries such as (α9)2(α10)3 or (α9)3(α10)2, and is highly expressed in cochlear and vestibular hair cells, immune cells, dorsal root ganglia, and select brain regions including frontal cortex, hippocampus, and medulla oblongata. It mediates central nervous system control of auditory and vestibular sensory processing through acetylcholine binding, which induces Ca2+ influx, activation of Ca2+-dependent K+ (SK2) channels, and hair cell hyperpolarization, distinguishing it from other nAChRs by its antagonism by nicotine and block by strychnine or bicuculline. Unlike most nAChRs, functional α9α10 assembly strictly requires ligand binding (e.g., ACh or antagonists like α-Bgtx) for surface expression. In disease, it contributes to noise-induced hidden hearing loss and presbycusis via efferent innervation of outer hair cells, with upregulated expression in knockout models suggesting compensatory roles with α7 nAChRs. Therapeutically, potent antagonists like α-conotoxin RgIA bind selectively at α9 interfaces, offering potential for chronic pain treatment by inhibiting this receptor in sensory neurons. Its unique pharmacology and restricted expression profile make it an attractive drug target, though challenges include avoiding auditory side effects.

Other names
α9α10 nicotinic acetylcholine receptorneuronal acetylcholine receptor α9α10nAChR α9α10
02

Mechanism of action

Selective antagonism at α9(+)/α9(−) or α10(+)/α9(−) binding sites (e.g., RgIA blocks channel opening), Agonism by acetylcholine leading to Ca2+ influx and SK2 channel activation/hyperpolarization, Ligand-dependent assembly and surface expression

03

Biological functions

Signal transductionSensory processing (auditory and vestibular)
04

Disease associations

Hearing loss (noise-induced, hidden hearing loss, presbycusis)Chronic painNeurodegenerative disease
05

Safety considerations

Potential disruption of auditory/vestibular sensory processingOff-target effects on immune cells or brain regions due to expression in non-neuronal tissues
06

Interacting drugs

α-conotoxin RgIA

5 more in the full profile.

Beyond the preview

Go deeper on Nicotinic acetylcholine receptor α9α10 subtype (α9α10 nAChR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nicotinic acetylcholine receptor α9α10 subtype (α9α10 nAChR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call